longbridgelongbridge
  • Products
  • Fees
  • Download
  • Promotions
    Welcome RewardsReferral ProgramUS Pre-Market Options Trading
  • For Institutions
    Corporate ServicesDevelopers
  • Help
  • About
    About LongbridgeLicense & RegulatoryMedia CoverageJoin Us
longbridge
  • Home
  • Discover
    Discover
    Global MarketsStock ScreenerFinancial Calendar
  • News & Info
    News & Info
    NewsInsightsLiveAcademy
  • Watchlist
  • Trade
  • Notification
  • LongbridgeAI
Home
Discover
News & Info
Watchlist
Trade
LongbridgeAI
Quote ListQuote List

Nabriva Therapeutics plc(NBRVF.US)

Last Updated 19:00:00 ET
longbridge loading
News
Financials
Overview

Keenova Reports First Quarter 2026 Financial Results | MNK Stock News

StockTitan·05/12/2026 10:30
US
SEOVF
-6.76%
US
ITRM
0.00%
US
NBRVF
0.00%
StockTitan·05/12/2026 10:30
US
SEOVF
-6.76%
US
ITRM
0.00%
US
NBRVF
0.00%

Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking | MNK Stock News

StockTitan·05/04/2026 11:30
US
NBRVF
0.00%
US
ITRM
0.00%
US
SEOVF
-6.76%
StockTitan·05/04/2026 11:30
US
NBRVF
0.00%
US
ITRM
0.00%
US
SEOVF
-6.76%

Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week | MNK Stock News

StockTitan·05/01/2026 11:30
US
ITRM
0.00%
US
NBRVF
0.00%
US
SEOVF
-6.76%
StockTitan·05/01/2026 11:30
US
ITRM
0.00%
US
NBRVF
0.00%
US
SEOVF
-6.76%

06:30 ETKeenova Announces Unaudited Fourth Quarter 2025 Financial Results

prnewswire·03/31/2026 18:30
US
LABU
+8.38%
US
BBH
+0.33%
US
NBRVF
0.00%
prnewswire·03/31/2026 18:30
US
LABU
+8.38%
US
BBH
+0.33%
US
NBRVF
0.00%

Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at the SHM Converge | MNK Stock News

StockTitan·03/27/2026 11:30
US
RNVA
0.00%
US
SEOVF
-6.76%
StockTitan·03/27/2026 11:30
US
RNVA
0.00%
US
SEOVF
-6.76%

REG - AIM - AIM Notice - 26/02/2026

London Stock Exchange·02/26/2026 16:00
US
ITRM
0.00%
US
ALLR
+1.41%
US
IBB
+1.85%
London Stock Exchange·02/26/2026 16:00
US
ITRM
0.00%
US
ALLR
+1.41%
US
IBB
+1.85%
© 2026 Longbridge|Disclaimer

Event Tracking

Nov11
Nabriva Therapeutics plc released FY2022 Q3 earnings on November 10 After-Market EST, actual revenue $9.153M (forecast $10.68M), actual EPS -$4.2133
00:00

Schedules & Filings

Schedules
Filings
Oct19
Earning Release(EST)

FY2023 Q2 Earning Release (USD) Revenue 2.243 M, Net Income -12.06 M, EPS -3.7334

May22
Earning Release(EST)

FY2023 Q1 Earning Release (USD) Revenue 7.59 M, Net Income -8.7 M, EPS -2.7174

Apr17
Earning Release(EST)

FY2022 Q4 Earning Release (USD) Revenue 10.57 M, Net Income -22.78 M, EPS -7.3249

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MWC
10.920
+131.36%
+6.200
SLXN
0.5650
+110.04%
+0.301
FSHPR
0.1666
+105.43%
+0.086
GCL
0.7458
+72.76%
+0.314
UZX
0.5351
+58.36%
+0.187
PETZ
1.235
+52.47%
+0.420
JUNS
0.4736
+48.00%
+0.151
CAPS
0.4185
+37.08%
+0.113
AMPGR
0.6790
+35.80%
+0.179
PHGE
0.5068
+35.51%
+0.127
View More